Viral Vector and pDNA Gene Therapy Products and Services Now Available

 

FEATURED STORY

Nov 18 2021

3D illustration of Adenovirus, a DNA-virus which causes respiratory and other infections.

New addition of viral vector and plasmid products and services to CDMO service offering

Vigene Biosciences, a leading contract development and manufacturing organization (CDMO), A Charles River Company, features integrated plasmid and viral vector production and analytical service offerings from its 110,000 sq. ft. of state-of-the-art facility with over 15 GMP cleanroom suites.

Review of Custom and Off-The-Shelf Products and Services

For research use, Vigene develops, manufacturers, and distributes both custom and off-the-shelf AAV, lentivirus, retrovirus, adenovirus, and plasmid-based reagents including HHMI/Janelia Research Campus AAV Biosensors.

For clinical use, Vigene offers FDA and EMA compliant production for AAV, lentivirus, adenovirus, retrovirus, and plasmids to global pharmaceutical and biotech companies, governmental agencies and non-profit organizations.

In addition, Vigene is supporting the cell and gene therapy community with the need of AAV reference materials, both full capsids and empty capsids, to facilitate AAV manufacturing, process development and analytical method development. The newly launched off-the-shelf and GMP-R AAV packaging plasmids help to offer shorter lead times with GMP AAV phase I production.

Interested to learn more about our gene therapy products?

Connect with an expert